日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global analysis of protein degradation reveals instability of diverse regulators in Escherichia coli

对蛋白质降解的全球分析揭示了大肠杆菌中多种调节因子的不稳定性

MacKrell, Elliot J; Lomenick, Brett; Qiu, Yanping; Jeckel, Hannah; Jones, Jeff; Chou, Tsui-Fen; Tirrell, David A

Associations between 24-h movement behaviors and optimal mental health of Chinese university students: a compositional data analysis

中国大学生24小时运动行为与最佳心理健康状况之间的关联:一项基于成分数据分析的研究

Li, Chenlin; Qiu, Yanping; Zheng, Nan; Liu, Yuwei; Yang, Xinglong; Wang, Lijuan

Discovery of acylsulfenic acid-featuring natural product sulfenicin and characterization of its biosynthesis

发现天然产物亚磺酸酯类化合物亚磺酸,并对其生物合成途径进行表征。

Xue, Dan; Zou, Hongbin; Qiu, Yanping; Lv, Wei; Madden, Michael D; Xu, Mingming; Lian, Xiaoying; Pulliam, Conor; Older, Ethan A; Hou, Lukuan; Campbell, Andrew; de Rond, Tristan; Awakawa, Takayoshi; Yuan, Chunhua; Moore, Bradley S; Li, Jie

PLAA/UFD-3 regulates P-bodies through its intrinsic disordered domain.

PLAA/UFD-3 通过其固有无序结构域调节 P 小体

Das Alakananda, Qiu Yanping, Wolf Trevor J, Brissett Ella, Cho Jaehyoung, Park Heenam, Chen Eugene C, Chou Tsui-Fen, Sternberg Paul W

Daily activity accumulation patterns and depressive symptoms among adolescents: a latent profile approach

青少年日常活动累积模式与抑郁症状:一种潜在剖面分析方法

Liu, Yuwei; Zheng, Nan; Chen, Huan; Liang, Guo; Li, Ting; Qiu, Yanping

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM313 in Healthy Participants: An Open-Label/Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial

CM313在健康受试者中的药代动力学、药效学和免疫原性:一项开放标签/双盲、随机、安慰剂对照的I期试验

Yu, Shuyan; Wu, Junzhen; Zhao, Junxue; He, Jinjie; Yan, Hongyue; Zhang, Xiang; Yang, Yifan; Song, Han; Hou, Qiaoyun; Guo, Bujing; Qiu, Yanping; Chen, Bo; Xue, Yu; Zhang, Jing

Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease

源自 AAV2/8 载体基因治疗法布里病的探索性研究的系统基因治疗

Mulan Deng #, Hongyu Zhou #, Shaomei He, Haoheng Qiu, Yanping Wang, April Yuanyi Zhao, Yunping Mu, Fanghong Li, Allan Zijian Zhao

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia

艾格列净在二甲双胍单药治疗血糖控制不佳的亚洲2型糖尿病患者中的安全性和有效性:VERTIS Asia研究

Ji, Linong; Liu, Yanmei; Miao, Heng; Xie, Yongli; Yang, Ming; Wang, Wei; Mu, Yuting; Yan, Ping; Pan, Sharon; Lauring, Brett; Liu, Shu; Huyck, Susan; Qiu, Yanping; Terra, Steven G

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

在二甲双胍控制不佳的 2 型糖尿病患者中,埃格列净联合西格列汀与单独使用任一药物治疗 52 周的疗效比较:VERTIS FACTORIAL 随机试验

Pratley, Richard E; Eldor, Roy; Raji, Annaswamy; Golm, Gregory; Huyck, Susan B; Qiu, Yanping; Sunga, Sheila; Johnson, Jeremy; Terra, Steven G; Mancuso, James P; Engel, Samuel S; Lauring, Brett

Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension

较低的ADD1基因启动子DNA甲基化增加原发性高血压的风险

Li-Na Zhang, Pan-Pan Liu, Lingyan Wang, Fang Yuan, Leiting Xu, Yanfei Xin, Li-Juan Fei, Qi-Long Zhong, Yi Huang, Limin Xu, Ling-Mei Hao, Xu-Jun Qiu, Yanping Le, Meng Ye, Shiwei Duan